Pfizer (PFE) Short-Term Debt issuances (2009 - 2026)

Pfizer (PFE) has reported Short-Term Debt issuances for 18 consecutive years, with $64.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short-Term Debt issuances fell 57.62% year-over-year to $64.0 million in Q2 2026; TTM through Jun 2026 was -$63.0 million, a 100.34% decrease from a year earlier, with the FY2025 full-year figure at $2.2 billion, down 80.41% from the prior year.
• Short-Term Debt issuances was $64.0 million for Q2 2026 at Pfizer, up from -$127.0 million in the prior quarter.
• Over five years, Short-Term Debt issuances peaked at $8.2 billion in Q3 2024 and troughed at -$2.0 billion in Q1 2024.
• A 5-year average of $2.1 billion and a median of $188.5 million in 2023 frame the typical range for Short-Term Debt issuances.
• The widest YoY moves for Short-Term Debt issuances: up 4047.55% in 2024, down 1002.21% in 2024.
• Over 5 years, Short-Term Debt issuances stood at $4.2 billion in 2022, then advanced by 9.43% to $4.6 billion in 2023, then surged by 76.53% to $8.2 billion in 2024, then plunged by 98.15% to $151.0 million in 2025, then sank by 57.62% to $64.0 million in 2026.
• The last three Short-Term Debt issuances figures came in at $64.0 million (Q2 2026), -$127.0 million (Q1 2026), and $151.0 million (Q2 2025), per Business Quant data.